<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01754909</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-004-12S</org_study_id>
    <secondary_id>1I01CX000569-01A2</secondary_id>
    <nct_id>NCT01754909</nct_id>
  </id_info>
  <brief_title>Mitigation of Radiation Pneumonitis and Fibrosis</brief_title>
  <official_title>Mitigation of Radiation Pneumonitis and Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project will test the effect of enalapril to mitigate the lung damage that can occur as&#xD;
      a side effect of radiation therapy for lung cancer or other intrathoracic cancers. Thousands&#xD;
      of Veterans develop lung cancer every year, and are treated by radiation therapy. Studies of&#xD;
      lung radiation injury in laboratory animals show that with enalapril, investigators can&#xD;
      significantly reduce the severity of radiation injury to the lung. Enalapril is FDA approved&#xD;
      and in common use for treatment of hypertension, kidney disease, and heart failure. These&#xD;
      studies will advance that work to human use. Successful mitigation of lung radiation damage&#xD;
      will improve the quality of life in Veterans and non-Veterans who are treated for lung cancer&#xD;
      by radiation, and may also improve cure rates of radiation therapy for lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim 1: To test the benefit of enalapril, an angiotensin-converting-enzyme-inhibitor, to&#xD;
      mitigate radiation pneumonitis and fibrosis in humans.&#xD;
&#xD;
      Subjects&#xD;
&#xD;
      Men and women undergoing radiation therapy for lung cancer or other intrathoracic cancers at&#xD;
      the Baltimore the Milwaukee or Ann Arbor Veterans Affairs Hospital are eligible. Subjects&#xD;
      will be recruited to this phase 2 trial after their diagnosis of cancer and after referral to&#xD;
      Radiation Oncology for treatment. The existence of this study will be posted in the Radiation&#xD;
      Oncology clinics. Dr Cohen, Dr Beth Gore, and Dr Michelle Mierzwa (co-investigators) and our&#xD;
      study coordinators will ensure recruitment. The informed consent process will be done by Dr&#xD;
      Cohen or Gore or Dr Mierzwa or the study coordinators. Subjects who require radiation therapy&#xD;
      to attempt to cure or to palliate their disease will be eligible for this study. Subjects&#xD;
      eligible for surgical resection and who do not need radiation therapy will not be eligible&#xD;
      for this study. Subjects on ACE inhibitors, angiotensin blockers, or renin antagonists will&#xD;
      be excluded. Use of other antihypertensives is not an exclusion criterion. There will be no&#xD;
      inclusion or exclusion by race or ethnic origin. Women and minorities are eligible. Children&#xD;
      are not eligible because children do not develop lung cancer. Previous surgery and past or&#xD;
      current use of chemotherapy are not exclusions. Subjects will have a Karnofsky performance&#xD;
      status &gt;/=70, absolute neutrophils &gt; 1000/mm^3, platelets &gt; 75,000/mm^3, and hematocrit &gt;&#xD;
      25%. Liver and kidney function tests will be within normal range and baseline blood pressure&#xD;
      will be systolic &gt; 110 mmHg sitting. Pregnant or nursing subjects are excluded and fertile&#xD;
      patients will use contraception. Lung function tests including spirometry, lung volumes and&#xD;
      diffusing capacity will be obtained as part of standard of care for patients prior to&#xD;
      radiotherapy, but indices from lung function tests will not be a cause for exclusion.&#xD;
&#xD;
      The mean lung dose will be &gt;/= 18 Gy and/or V20 &gt;20%. Radiation will be delivered with&#xD;
      standard fractionation schedule of 1.8 to 2 Gy per day, 5 days per week, without planned&#xD;
      treatment breaks.&#xD;
&#xD;
      Experimental design&#xD;
&#xD;
      Radiation treatment starts at time 0, and is given to completion, as indicated. Enalapril or&#xD;
      placebo are started after the first radiation treatment fraction and continued thereafter.&#xD;
      The renin-angiotensin system is tested at time 0, at three weeks, and at the completion of&#xD;
      radiation treatment. CT scanning is done at time 0 and every three months thereafter for the&#xD;
      first two years. Median survival is expected to be 18 months.&#xD;
&#xD;
      Subjects will undergo therapeutic irradiation as indicated for clinical care. They will be&#xD;
      enrolled to this masked, phase 2 trial at the start of radiation therapy (RT), stratified for&#xD;
      cancer stage, then randomized to enalapril or identical-appearing placebo. Randomization will&#xD;
      be done by the Department of Biostatistics, Medical College of Wisconsin, using random number&#xD;
      tables; the center pharmacies will be notified of the assignment to enalapril or placebo.&#xD;
      There will be no stratification by age, gender, lung cancer histology, or use of chemotherapy&#xD;
      since these do not have a consistent relation with the occurrence of RP . Use of enalapril or&#xD;
      placebo will not be known to the patients or their physicians during the time of study. The&#xD;
      medical center pharmacy will stock and provide the study drug. Study drug, enalapril or&#xD;
      placebo, will be started after the first fraction of the RT, at 2.5 mg by mouth once a day&#xD;
      and increased to 10 mg/day in weekly increments as tolerated. Routine clinical care during&#xD;
      the course of irradiation includes weekly or more frequent clinical assessment and vital&#xD;
      signs. Blood testing for kidney function and potassium will occur within ten days after start&#xD;
      of study drug. Additional patient visits will not occur for this study alone. Additional&#xD;
      blood testing will occur in usual clinical care and will also be recorded. Routine care,&#xD;
      independent of this study, includes CT scan chest imaging every three months for the first&#xD;
      two years of follow-up. The study drug will be continued for life.&#xD;
&#xD;
      Endpoints for injury&#xD;
&#xD;
      The primary endpoint is symptomatic grade 2 or higher radiation pneumonitis, as defined by&#xD;
      the established criteria, within the first 4 months of irradiation. The NCI Common&#xD;
      Terminology Criteria Adverse Event (CTCAE) version 4.0 will be used to grade pulmonary&#xD;
      toxicity. CTCAE is a worldwide standard for reporting adverse events from all modalities on&#xD;
      cancer clinical trials. Pneumonitis is a new-onset and persistent cough requiring&#xD;
      anti-tussive agents and or dyspnea with effort that is unexplained by other pulmonary&#xD;
      illness. It may last for days to weeks. Severe cases may evolve to respiratory failure. Use&#xD;
      of such patient-reported symptoms is strongly recommended for cancer-related clinical trials.&#xD;
      Radiographic changes of RP occur in over half of subjects undergoing therapeutic thoracic&#xD;
      irradiation; radiographic RP will be a secondary endpoint. Classic radiographic&#xD;
      manifestations of RP are increased lung density within the radiation field within the first&#xD;
      six months after radiation therapy that is not explained by infection or cancer. radiographic&#xD;
      pneumonitis will be recorded by two investigators (Drs Gore and Antonescu-Turcu, EG, AAT),&#xD;
      using the scale reported by Guckenberger. Investigators expect a radiographic rate of RP of&#xD;
      50%.&#xD;
&#xD;
      Investigators expect almost all surviving subjects to have fibrosis by CT scanning at 6 and&#xD;
      12 months, and will test this as another major endpoint. Radiation fibrosis in the lung is&#xD;
      evident as scarring with volume loss and bronchiectasis within the radiation field at six&#xD;
      months or more after radiation therapy, not explained by infection or cancer. radiographic&#xD;
      fibrosis will be recorded and quantified by two investigators (EG, AAT). Reduction in&#xD;
      diffusion capacity for carbon monoxide (DLCO) correlates with pulmonary radiation fibrosis.&#xD;
      DLCO is obtained in all survivors at the 12 month time point, and will be compared to&#xD;
      baseline values as an additional secondary endpoint. The occurrence of clinical grade 2 or&#xD;
      higher RP, of radiographic RP and fibrosis as dichotomous variables, will be compared for the&#xD;
      subjects on enalapril compared to those on placebo. For RP, any image showing RP will assign&#xD;
      a subject to the RP group. For fibrosis, the last CT scan will be used.&#xD;
&#xD;
      Investigators will test quality of life as a secondary endpoint. The Functional Assessment of&#xD;
      Cancer Therapy -lung (FACT-L version 4) will be used to assess Quality of Life (QoL). FACT-L&#xD;
      contains four general (physical, social/family, emotional, and functional well being) and one&#xD;
      lung cancer specific subscale. QoL will be assessed pretreatment, and at 12 months post&#xD;
      treatment. Use of patient-reported data is strongly recommended for cancer-related clinical&#xD;
      trials.&#xD;
&#xD;
      Aim 2: To test the mechanism of mitigation by enalapril&#xD;
&#xD;
      Subjects These are the same subjects as in aim 1.&#xD;
&#xD;
      Experimental design Investigators will test the major components of the renin-angiotensin&#xD;
      system; angiotensinogen, plasma renin activity, and angiotensin II (ang II). These will be&#xD;
      measured at baseline, at three weeks after the start of irradiation, and at the completion of&#xD;
      irradiation. Investigators will test their mechanistic involvement by their change with use&#xD;
      of enalapril, in particular whether the benefit of enalapril is correlated with its effect to&#xD;
      lower the plasma ang II levels. Other components of the RAS, including angiotensin (1-7),&#xD;
      aldosterone, AcSDKP, and bradykinin will not be tested because experimental studies have not&#xD;
      shown them to be relevant to mitigation of normal tissue radiation injury.&#xD;
&#xD;
      Baseline elevation of one or more of these RAS components, compared to known levels in the&#xD;
      normal population, may correlate with development of RP and or fibrosis in the control,&#xD;
      placebo group. This may permit better focused use of mitigators in the future, in only those&#xD;
      at risk.&#xD;
&#xD;
      Enalapril, by inhibition of ACE, will reduce plasma ang II and lead to a feedback elevation&#xD;
      of PRA. This will confirm adherence to drug therapy and may also correlate with its benefit.&#xD;
      Elevation of PRA in subjects on enalapril, but without mitigation benefit, will show that it&#xD;
      is ineffective, despite its adequate bioavailability.&#xD;
&#xD;
      Aim 3: To confirm that enalapril does not adversely affect cancer treatment outcomes.&#xD;
&#xD;
      Subjects These are the same subjects as in aim 1.&#xD;
&#xD;
      Experimental design Investigators will compare cancer recurrence and cancer-related survival&#xD;
      in subjects on enalapril versus placebo. Cancer recurrence will be assessed clinically, as&#xD;
      confirmed by CT imaging and or histology. The RECIST criteria will be used. Recurrence rates&#xD;
      and survival will be assessed by interim safety analyses during the study, and finally at its&#xD;
      completion. In the statistical analysis, investigators will account for the effects of&#xD;
      interim sampling for the safety analyses, and will adjust for patient and disease&#xD;
      characteristics as well as missing data. A benefit of enalapril on RP may enhance patient&#xD;
      survival. An adverse effect of enalapril on survival will stop this study. But a cohort of&#xD;
      162 Veterans showed no difference in patient survival for those on ACE inhibitor compared to&#xD;
      those not on ACE inhibitor. Thus, investigators do not expect adverse changes in recurrence&#xD;
      rates or patient survival.&#xD;
&#xD;
      Expected results, potential problems, and long-term impact&#xD;
&#xD;
      Investigators expect that subjects on enalapril will have significantly less clinical and&#xD;
      radiographic RP and fibrosis, compared to those on placebo. Investigators expect that&#xD;
      subjects on placebo who develop RP and or fibrosis may have baseline elevation of AGT and PRA&#xD;
      compared to those who don't develop RP and or fibrosis, and that the mitigation benefit of&#xD;
      enalapril will correlate with its effect to increase the PRA and reduce the plasma ang II&#xD;
      levels. Investigators expect that enalapril will not increase cancer-related mortality, and&#xD;
      may even enhance overall patient survival through mitigation of radiation lung injury.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2013</start_date>
  <completion_date type="Actual">April 1, 2018</completion_date>
  <primary_completion_date type="Actual">April 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Radiation Pneumonitis</measure>
    <time_frame>two years</time_frame>
    <description>The clinical occurrence and grade of radiation pneumonitis, by National Cancer Institute Common Terminology Criteria Adverse Event grading ( NCI CTCAE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Radiation Pneumonitis by CT Scan</measure>
    <time_frame>six months</time_frame>
    <description>The occurrence and grade of radiation pneumonitis by radiographic criteria, using CT scanning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Radiation Fibrosis</measure>
    <time_frame>one year</time_frame>
    <description>The occurrence and grade of radiation fibrosis by radiographic criteria, using CT scanning</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Radiation Pneumonitis</condition>
  <arm_group>
    <arm_group_label>enalapril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use of enalapril in subjects undergoing radiotherapy for lung cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Use of placebo in subjects undergoing radiotherapy for lung cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enalapril</intervention_name>
    <description>Enalapril once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer</description>
    <arm_group_label>enalapril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo, once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women undergoing radiation therapy to the chest for cancer at the Baltimore,&#xD;
             the Milwaukee, and Ann Arbor Veterans Affairs Hospital are eligible.&#xD;
&#xD;
          -  Subjects who require radiation therapy to attempt to cure or to palliate their disease&#xD;
             will be eligible for this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects eligible for surgical resection and who do not need radiation therapy will&#xD;
             not be eligible for this study.&#xD;
&#xD;
          -  Subjects who must remain on ACE inhibitors, angiotensin blockers, or renin antagonists&#xD;
             will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric P Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Ann Arbor Healthcare System, Ann Arbor, MI</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clement J. Zablocki VA Medical Center, Milwaukee, WI</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53295-1000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kharofa J, Cohen EP, Tomic R, Xiang Q, Gore E. Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy. Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):238-43. doi: 10.1016/j.ijrobp.2011.11.013. Epub 2012 Jan 31.</citation>
    <PMID>22300564</PMID>
  </results_reference>
  <results_reference>
    <citation>Citrin DE, Prasanna PGS, Walker AJ, Freeman ML, Eke I, Barcellos-Hoff MH, Arankalayil MJ, Cohen EP, Wilkins RC, Ahmed MM, Anscher MS, Movsas B, Buchsbaum JC, Mendonca MS, Wynn TA, Coleman CN. Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate. Report of an NCI Workshop, September 19, 2016. Radiat Res. 2017 Jul;188(1):1-20. doi: 10.1667/RR14784.1. Epub 2017 May 10.</citation>
    <PMID>28489488</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 29, 2012</study_first_submitted>
  <study_first_submitted_qc>December 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2012</study_first_posted>
  <results_first_submitted>June 14, 2019</results_first_submitted>
  <results_first_submitted_qc>September 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 1, 2019</results_first_posted>
  <last_update_submitted>September 30, 2019</last_update_submitted>
  <last_update_submitted_qc>September 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung cancer</keyword>
  <keyword>radiation pneumonitis</keyword>
  <keyword>mitigation</keyword>
  <keyword>enalapril</keyword>
  <keyword>placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Radiation Pneumonitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enalapril</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT01754909/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT01754909/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>50 consented</recruitment_details>
      <pre_assignment_details>Verification of eligibility.&#xD;
Seven did not start study drug. Six of those because found ineligible after enrollment. One of those because of early termination of study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Enalapril</title>
          <description>Use of enalapril in subjects undergoing radiotherapy for lung cancer.&#xD;
Enalapril: Enalapril once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Use of placebo in subjects undergoing radiotherapy for lung cancer&#xD;
placebo: Placebo, once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Enalapril</title>
          <description>Use of enalapril in subjects undergoing radiotherapy for lung cancer.&#xD;
Enalapril: Enalapril once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Use of placebo in subjects undergoing radiotherapy for lung cancer&#xD;
placebo: Placebo, once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>absence of pneumonitis or fibrosis</title>
          <description>as per clinical asessment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Radiation Pneumonitis</title>
        <description>The clinical occurrence and grade of radiation pneumonitis, by National Cancer Institute Common Terminology Criteria Adverse Event grading ( NCI CTCAE)</description>
        <time_frame>two years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>Use of enalapril in subjects undergoing radiotherapy for lung cancer.&#xD;
Enalapril: Enalapril once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Use of placebo in subjects undergoing radiotherapy for lung cancer&#xD;
placebo: Placebo, once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Radiation Pneumonitis</title>
          <description>The clinical occurrence and grade of radiation pneumonitis, by National Cancer Institute Common Terminology Criteria Adverse Event grading ( NCI CTCAE)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Occurrence rates, comparison by t test</non_inferiority_desc>
            <p_value>0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Radiation Pneumonitis by CT Scan</title>
        <description>The occurrence and grade of radiation pneumonitis by radiographic criteria, using CT scanning</description>
        <time_frame>six months</time_frame>
        <population>analyzed by CT scan readings done in a masked fashion</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>Use of enalapril in subjects undergoing radiotherapy for lung cancer.&#xD;
Enalapril: Enalapril once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Use of placebo in subjects undergoing radiotherapy for lung cancer&#xD;
placebo: Placebo, once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Radiation Pneumonitis by CT Scan</title>
          <description>The occurrence and grade of radiation pneumonitis by radiographic criteria, using CT scanning</description>
          <population>analyzed by CT scan readings done in a masked fashion</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Radiation Fibrosis</title>
        <description>The occurrence and grade of radiation fibrosis by radiographic criteria, using CT scanning</description>
        <time_frame>one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>Use of enalapril in subjects undergoing radiotherapy for lung cancer.&#xD;
Enalapril: Enalapril once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Use of placebo in subjects undergoing radiotherapy for lung cancer&#xD;
placebo: Placebo, once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Radiation Fibrosis</title>
          <description>The occurrence and grade of radiation fibrosis by radiographic criteria, using CT scanning</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>lifetime of subject or until study end April 2018, an average of 2 years</time_frame>
      <desc>Hospitalization or death</desc>
      <group_list>
        <group group_id="E1">
          <title>Enalapril</title>
          <description>Use of enalapril in subjects undergoing radiotherapy for lung cancer.&#xD;
Enalapril: Enalapril once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Use of placebo in subjects undergoing radiotherapy for lung cancer&#xD;
placebo: Placebo, once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>death or hospitalization</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>hospitalization</sub_title>
                <description>not death</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Eric Cohen</name_or_title>
      <organization>Baltimore VAMC</organization>
      <phone>410 605 7000 ext 5/7182</phone>
      <email>eric.cohen@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

